文献速递腹部MR

多参数MRI影像组学特征鉴别小(< 2 cm)胰腺导管腺癌与神经内分泌肿瘤

Differentiating small (< 2 cm) pancreatic ductal adenocarcinoma from neuroendocrine tumors with multiparametric MRI-based radiomic features.
PubMed 文献 · Eur Radiol · 2024-06-13

本研究回顾性纳入两中心197例患者(训练队列146例、验证队列51例),从T2加权、扩散加权、T1加权、动脉期、门静脉期及延迟期成像提取7338个影像组学特征构建Rad-score,并联合CA19-9、肿瘤边缘、胰管扩张构建融合模型;融合模型在训练与验证队列的AUC分别为0.977和0.941,表现最佳。

要点

  • 基于多参数MRI的Rad-score可用于鉴别小PDAC与PNET,验证队列AUC为0.930。
  • 融合模型纳入CA19-9、肿瘤边缘、胰管扩张和Rad-score,验证队列AUC为0.941。
  • 术前鉴别小PDAC与PNET具有挑战性,影像组学模型可提供辅助鉴别信息。

核心结论

  • 基于MR的Rad-score是鉴别小PDAC与PNET的新型图像生物标志物;融合影像组学、影像学及临床特征的融合模型在鉴别这两类肿瘤方面表现很好。

研究设计与样本

  • 两中心回顾性收集197例患者(训练队列146例、验证队列51例),从T2加权、扩散加权、T1加权、动脉期、门静脉期和延迟期成像提取7338个影像组学特征,经Mann-Whitney U检验、Spearman秩相关检验和LASSO方法筛选最优特征构建Rad-score,并采用多变量逻辑回归构建影像学模型、影像组学模型和融合模型。

诊断标准与关键数值

  • 影像组学模型基于Rad-score,训练队列AUC为0.905、敏感度为0.780、特异度为0.906、准确率为0.836;验证队列AUC为0.930、敏感度为0.800、特异度为0.952、准确率为0.863。
  • 融合模型纳入CA19-9、肿瘤边缘、胰管扩张和Rad-score,训练队列AUC为0.977、敏感度为0.914、特异度为0.954、准确率为0.932;验证队列AUC为0.941、敏感度为0.852、特异度为0.950、准确率为0.894。

临床应用与阅片要点

  • 作者认为,联合MR影像组学、影像学及临床特征的融合模型有助于鉴别小胰腺导管腺癌与胰腺神经内分泌肿瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess MR-based radiomic analysis in preoperatively discriminating small (< 2 cm) pancreatic ductal adenocarcinomas (PDACs) from neuroendocrine tumors (PNETs).

METHODS: A total of 197 patients (146 in the training cohort, 51 in the validation cohort) from two centers were retrospectively collected. A total of 7338 radiomics features were extracted from T2-weighted, diffusion-weighted, T1-weighted, arterial phase, portal venous phase and delayed phase imaging. The optimal features were selected by the Mann-Whitney U test, Spearman's rank correlation test and least absolute shrinkage and selection operator method and used to construct the radiomic score (Rad-score). Conventional radiological and clinical features were also assessed. Multivariable logistic regression was used to construct a radiological model, a radiomic model and a fusion model.

RESULTS: Nine optimal features were identified and used to build the Rad-score. The radiomic model based on the Rad-score achieved satisfactory results with AUCs of 0.905 and 0.930, sensitivities of 0.780 and 0.800, specificities of 0.906 and 0.952 and accuracies of 0.836 and 0.863 for the training and validation cohorts, respectively. The fusion model, incorporating CA19-9, tumor margins, pancreatic duct dilatation and the Rad-score, exhibited the best performance with AUCs of 0.977 and 0.941, sensitivities of 0.914 and 0.852, specificities of 0.954 and 0.950, and accuracies of 0.932 and 0.894 for the training and validation cohorts, respectively.

CONCLUSIONS: The MR-based Rad-score is a novel image biomarker for discriminating small PDACs from PNETs. A fusion model combining radiomic, radiological and clinical features performed very well in differentially diagnosing these two tumors.

CLINICAL RELEVANCE STATEMENT: A fusion model combining MR-based radiomic, radiological, and clinical features could help differentiate between small pancreatic ductal adenocarcinomas and pancreatic neuroendocrine tumors.

KEY POINTS: Preoperatively differentiating small pancreatic ductal adenocarcinomas (PDACs) and pancreatic neuroendocrine tumors (PNETs) is challenging. Multiparametric MRI-based Rad-score can be used for discriminating small PDACs from PNETs. A fusion model incorporating radiomic, radiological, and clinical features differentiated small PDACs from PNETs well.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Shen K, Su W, Liang C, et al. Differentiating small (< 2 cm) pancreatic ductal adenocarcinoma from neuroendocrine tumors with multiparametric MRI-based radiomic features. Eur Radiol. 2024. PMID: 38869639. doi:10.1007/s00330-024-10837-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。